- $797.40m
- $767.39m
- $407.32m
Brief: Ardelyx Q3 product sales USD 22.285 million
Ardelyx Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ardelyx Shares Positive Data On Symptom Response During Treatment With Ibsrela (Tenapanor) For IBS-C
U.S. STOCKS ON THE MOVE-Morgan Stanley, Procter & Gamble, Lululemon
Ardelyx gains as US FDA greenlights kidney disease-related drug
Brief: Ardelyx Announces Amendment Of Debt Financing Agreement With SLR Capital Partners To Provide $50 Million Of Additional Committed Capital
US FDA approves Ardelyx's kidney disease-related drug (updated)
US FDA approves Ardelyx's kidney disease-related drug
Brief: Ardelyx Says FDA Approves Xphozah, A First-In-Class Phosphate Absorption Inhibitor
REUTERS NEWS SCHEDULE AT 10:00 p.m. GMT/6:00 a.m. SGT
REUTERS NEWS SCHEDULE AT 10 a.m. GMT/6 a.m. ET
Brief: Ardelyx Shares Preliminary Data On Use Of Ibsrela® (Tenapanor) In Pediatric Ibs-C Patients
Brief: Ardelyx Announces Publication Of Positive Results From T3mpo-3 Long-Term Open-Label Safety Trial Of Tenapanor
Brief: Kyowa Kirin Co Says Tenapanor For Hyperphosphatemia Approved In Japan
U.S. RESEARCH ROUNDUP-Autodesk, Intuit, Workday
U.S. RESEARCH ROUNDUP-Apellis Pharmaceuticals, CDW, Equinix
Ardelyx Inc reports results for the quarter ended in June - Earnings Summary
Brief: Ardelyx Q2 Net Income USD -17.121 Mln
Ardelyx Inc expected to post a loss of 11 cents a share - Earnings Preview